Please login to the form below

Not currently logged in
Email:
Password:

CureVac

This page shows the latest CureVac news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolts on another immuno-oncology company

Boehringer bolts on another immuno-oncology company

Immunotherapeutics and earlier alliances with Siamab, AbeXXa Biologics, CureVac and Philogen.

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for lung cancer.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Boehringer Ingelheim has taken a licence to Curevac's messenger RNA vaccine for one of its compounds and the Californian company, Sutro, has signed an early stage deal with Merck KGaA

  • Pharma deals during July 2014 Pharma deals during July 2014

    Scandinavia. CureVac's relationship with Sanofi Pasteur dates back to 2011 when the companies entered into a collaboration and option agreement covering mRNA-based vaccines generated using CureVac's RNActive technology ... It will pay CureVac an

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    preclinical). 225. CureVac/ Sanofi Pasteur. Exercise of option,  licence. RNActive vaccine technology vs undisclosed pathogens (preclinical).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • CureVac’s CEO appointed to EC High Level Group CureVac’s CEO appointed to EC High Level Group

    Dr Ingmar Hoerr, chief executive officer of clinical-stage mRNA technology specialist CureVac, has been appointed to the European Commission's High Level Group for research and innovation programmes. ... He brings 17 years of experience as the founder

  • CureVac appoints chief financial officer CureVac appoints chief financial officer

    Pierre Kemula joins the mRNA company’s management board. Tübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer. ... Kemula will have responsibility for managing CureVac's financial and capital markets

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics